Invivyd (Nasdaq:IVVD) - Stock Price, News & Analysis

IVVD Stock Overview

A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More details

IVVD fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 99.2% below our estimate of its fair value

Earnings are forecast to grow 72.16% per year

Trading at good value compared to peers and industry

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($92M)

Invivyd, Inc. Competitors

X4 Pharmaceuticals

NasdaqCM:XFOR

US$62.8m

BioAtla

NasdaqGM:BCAB

US$72.5m

Prelude Therapeutics

NasdaqGS:PRLD

US$52.8m

Connect Biopharma Holdings

NasdaqGM:CNTB

US$53.9m

Price History & Performance

Summary of all time highs, changes and price drops for Invivyd
Historical stock prices
Current Share Price	US$0.77
52 Week High	US$5.20
52 Week Low	US$0.72
Beta	0.66
11 Month Change	-24.70%
3 Month Change	-12.53%
1 Year Change	-48.79%
33 Year Change	-95.90%
5 Year Change	n/a
Change since IPO	-96.32%

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

Shareholder Returns

	IVVD	US Biotechs	US Market
7D	-13.7%	-6.5%	-1.0%
1Y	-48.8%	14.6%	30.3%

Return vs Industry: IVVD underperformed the US Biotechs industry which returned 14.1% over the past year.

Return vs Market: IVVD underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	17.9%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IVVD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IVVD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2020	95	Bill Duke	invivyd.com

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

Invivyd, Inc. Fundamentals Summary

How do Invivyd's earnings and revenue compare to its market cap?
IVVD fundamental statistics
Market cap	US$91.79m
Earnings (TTM)	-US$225.14m
Revenue (TTM)	US$11.56m

7.9x

P/S Ratio

-0.4x

P/E Ratio

Is IVVD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVVD income statement (TTM)
Revenue	US$11.56m
Cost of Revenue	US$894.00k
Gross Profit	US$10.67m
Other Expenses	US$235.81m
Earnings	-US$225.14m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.88
Gross Margin	92.27%
Net Profit Margin	-1,946.87%
Debt/Equity Ratio	0%

How did IVVD perform over the long term?

See historical performance and comparison

IVVD Stock Overview

Rewards

Risk Analysis

Invivyd, Inc. Competitors

NasdaqCM:XFOR

US$62.8m

NasdaqGM:BCAB

US$72.5m

NasdaqGS:PRLD

US$52.8m

NasdaqGM:CNTB

US$53.9m

Price History & Performance

Recent News & Updates

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Recent updates

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven